CORRECTION article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Corrigendum: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma
Provisionally accepted
- 1Affiliated Hospital of Zunyi Medical University, Zunyi, China
- 2Zunyi Bozhou District People's Hospital, Zunyi, China
- 3Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Guiyang, China
- 4Guangxi Shenli Pharmaceutical Co., Ltd., Yulin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
• please read through all the templates before choosing • pick the most relevant text template(s) from the following page and delete all others.• edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated.
Keywords: cost-effectiveness analysis, Advanced hepatocellular carcinoma, Cabozantinib, atezolizumab, Sorafenib
Received: 30 Oct 2025; Accepted: 31 Oct 2025.
Copyright: © 2025 Zhu, He, Xia, Cao, Li, Cai and Bai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tongxia Xia, xtx0925@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.